Regeneron Pharmaceuticals
777 OLD SAW MILL RIVER ROADTARRYTOWN NY 10591 USA
P: 914-847-7000
http://www.regeneron.com
Profile
Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
Key Executives
Name | Title |
---|---|
Leonard S. Schleifer | CEO/Co-Chairman of the Board/Co-Founder/Co-President/Director |
Neil Stahl | Executive VP, Divisional |
George D. Yancopoulos | Chief Scientific Officer/Co-Chairman of the Board/Co-President/Director |
Joseph J. Larosa | Executive VP/General Counsel/Secretary |
Daniel P. Van Plew | Executive VP/General Manager, Divisional |
Marion McCourt | Executive VP, Divisional |
Christopher R. Fenimore | Chief Accounting Officer/Controller/Senior VP |
Andrew J Murphy | Executive VP, Divisional |
Jason Pitofsky | Controller/Vice President |